1800 202 8726
IHC Markers Explained

p16 Positive and HPV: — What Your Report Is Telling You

A p16-positive result appears on pathology reports for certain head and neck and cervical cancers. It tells your oncologist that HPV likely drove the tumour's development — and it places your cancer in a distinct clinical category from p16-negative disease.

Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed September 2026

  • Not the same as an HPV test — p16 is a protein detected in tumour tissue, not a test for the virus in your blood or body.
  • Two cancers, one marker — p16 is most used in oropharyngeal and cervical cancers, where HPV is a known driver.
  • A distinct clinical category — NCCN and ESMO classify p16-positive and p16-negative oropharyngeal cancer separately — they are staged and assessed differently.
  • Your oncologist reads the full panel — p16 is one marker. Its meaning depends on your cancer type, stage, and the rest of your pathology report.
4.8 · 800+ Google reviews · 15,000+ patients treated
Limited Slots Today

Get this explained properly

₹950   Today: FREE  ·  Including free written second opinion

Reply within 2 working hours
Report reviewed by a senior oncologist
Confidential. No commitment to start treatment.
or
Call 1800 202 8726
17+
Cancer Specialists
on Panel
96.9%
Breast Cancer
Survival Rate*
15,000+
Patients
Treated
4.8★
Google Rating
(800+ reviews)

p16 is a protein that accumulates in tumour cells when high-risk HPV is driving their growth. A positive result is used as a surrogate marker for HPV activity. NCCN and ESMO recognise p16-positive oropharyngeal and cervical cancers as biologically distinct from p16-negative disease, with a separate staging system and a different clinical course.

What does p16 actually measure?

p16 is a tumour-suppressor protein. Your cells normally use it to slow uncontrolled growth. When high-risk HPV infects a cell and disables its normal control system, p16 builds up to abnormally high levels — and that accumulation is what the test detects.

The laboratory uses IHC — immunohistochemistry — a staining technique applied to your biopsy tissue. A positive result requires staining that is both strong and widespread across the tumour cells. Faint or patchy staining is reported as negative.

A positive p16 result is a surrogate marker: it is reliable evidence that HPV likely caused the tumour, not a direct test for the virus in your body today.

What do the terms on my p16 report mean?

p16 (CDKN2A)
A tumour-suppressor protein. When high-risk HPV inactivates the cell's normal growth controls, p16 accumulates in large amounts — which is what the IHC test detects.
IHC (immunohistochemistry)
The staining technique used to detect p16 protein in biopsy tissue. No new biopsy is usually needed if your existing sample is adequate.
Strong diffuse staining
The pattern that counts as positive: the stain must be both intense and spread across most of the tumour cells, not limited to a small cluster.
Surrogate marker
A measurable sign used in place of another. p16 is a surrogate for high-risk HPV because it is faster and more reproducible than direct viral testing in this context.
p16-negative
Absent or minimal staining. p16-negative oropharyngeal cancer has a different risk profile, a different staging classification, and a different clinical course from p16-positive disease.

Still unclear?

Send your reports across and a specialist will walk you through what they mean — what is known, what is not, and what the options actually are.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Dr. Naresh Gundu
Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile
Dr. C. Raghavendra Reddy
Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile
Dr. Bharati Devi Gorantla
Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile
Dr. Owais Mohammed
Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile
Dr. T. Raghavender Reddy
Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile
Dr. N. Kiranmayee
Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile
Dr. Muralidhar Muddusetty
Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile
Dr. Raghavendra Naik
Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Mohammed  Imaduddin
Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Vinay Mamidala
Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile
Dr. Paila Gowri Naidu
Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile
Dr. Venkata Sushma P
Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile
Dr. Kirti Ranjan Mohanty
Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile
Dr. Gangadhar Vajrala
Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile
Dr. Basudev Pokhrel
Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile
Dr. Mohammed Imran
Interventional Radiologist

Dr. Mohammed Imran

View Profile
Dr. Vajja Sandeep Kumar
Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile
Dr. Sridhar Kamani
Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

Get a straight answer from a specialist

45 minutes, your reports reviewed, your questions answered in plain language.

Book Free Consultation Call 1800 202 8726

Why does p16 status change the clinical picture?

p16-positive oropharyngeal cancer — most often arising in the tonsils, base of tongue, or soft palate — is classified by NCCN, ASCO, and ESMO as a distinct disease from p16-negative oropharyngeal cancer. The two are staged separately.

p16-positive disease tends to respond differently to treatment than p16-negative disease. What that means for your individual situation depends on your stage and other findings. Your oncologist will explain the implications for your specific case.

In cervical pathology, p16 is used to confirm HPV involvement in dysplasia and cancer. It is often reported alongside Ki-67, and together they help classify the severity of the abnormality.

Questions families ask when they see this result

Does p16-positive mean my cancer was caused by HPV?

p16 positivity in oropharyngeal cancer is strong evidence that high-risk HPV — most often HPV-16 — drove the tumour's development. Your oncologist may rely on the p16 result as sufficient, or order additional HPV testing on the tissue, depending on your cancer type and the guidelines that apply. In cervical cancer, p16 positivity similarly confirms HPV involvement. The result describes how the tumour developed; it does not mean the virus is currently active or that you are contagious.

Is the HPV still active, or can I pass it on?

The p16 result describes tumour tissue, not your current viral status. HPV is sexually transmitted and very common; most people clear it without knowing. A positive pathology result does not mean the virus is still present or active in your body today. If you have concerns about your sexual health or your partner's risk, raise them with your oncologist or a sexual health physician — it is a reasonable question and one your team can address properly.

Why does p16-positive status seem to matter so much?

p16-positive oropharyngeal cancer, taken as a group, tends to respond differently to treatment than p16-negative disease — which is exactly why NCCN, ASCO, and ESMO classify the two separately and stage them using different systems. That said, this is a population-level observation. Your stage, your general health, and the rest of your pathology report all shape what it means for you. Your oncologist will explain the implications for your case, not for p16-positive patients in general.

What should I ask at my next appointment?

Three questions worth raising: what does the p16 result mean for how my cancer is staged; is any further biomarker testing needed before a treatment decision; and does this change the approach compared with p16-negative disease. Your oncologist can answer all three in relation to your specific situation. Writing the answers down helps — these conversations carry a great deal of information and can be hard to hold onto afterwards.

Explore 112 more Markers, Molecular Testing and Test Accuracy topics

HUB — How Accurate Is a Biopsy? Repeats, Errors and Second Opinions

HUB — IHC and Molecular Markers on a Biopsy

HUB — Labs, Slides and Second Opinions on a Biopsy

All Markers, Molecular Testing and Test Accuracy →

Next step

Still not sure what applies to you?

Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.

Book Free Consultation Call 1800 202 8726
Common questions

Frequently asked questions

What does p16 positive mean in a cancer report?

p16 is a protein that accumulates in tumour cells when high-risk HPV is driving their growth. A positive IHC result is used as a surrogate marker for HPV involvement — not a direct viral test. Your oncologist uses it alongside your stage, cancer type, and other pathology findings. For oropharyngeal and cervical cancers, it is an important part of how your disease is classified and staged.

Is a p16 positive result good or bad?

p16 status describes tumour biology, not outcome on its own. p16-positive oropharyngeal cancer is classified separately from p16-negative disease by NCCN, ASCO, and ESMO because the two behave differently as groups. What that means for you depends on your stage, health, and full pathology report. Ask your oncologist what the result means specifically for your case — a general good-or-bad label misses the individual detail that matters most.

Does p16 status affect what treatment I receive?

It can. p16 status informs treatment planning for oropharyngeal cancer because NCCN, ASCO, and ESMO classify p16-positive and p16-negative disease separately. How much it changes the specific approach depends on your stage and other findings. Treatment decisions belong to your oncologist. Your team will explain what the result means for the plan being considered for you.

Which cancers are routinely tested for p16?

p16 testing is most established in oropharyngeal squamous cell carcinoma — cancers of the tonsil, base of tongue, and soft palate — and in cervical pathology, where it helps classify dysplasia and cancer. Some other head and neck cancers may be tested depending on clinical context. Your oncologist can explain whether p16 testing was relevant to your specific report and what it adds to your overall assessment.

How is p16 tested in the laboratory?

p16 is detected by IHC — immunohistochemistry — a staining technique applied to your biopsy tissue. No new procedure is usually needed if your existing sample is adequate. A pathologist reads the staining pattern: a positive result requires both intensity and widespread distribution across the tumour cells. Results form part of your pathology report and typically take a few days to two weeks from when the sample reaches the laboratory.

What if my p16 result is borderline or unclear?

Some results fall between clearly positive and clearly negative and are reported as equivocal. In those situations, your oncologist may request a review by a second pathologist or order additional molecular testing. We do not yet have universally agreed thresholds for borderline cases, and guidance from NCCN and ESMO continues to be refined. Your treating team will explain how an uncertain result will be handled in the context of your overall care.

Full index

Browse all 701 biopsy topics

Every page in this section, grouped by the part of the journey it belongs to. Pick a group to see what is in it.

What Is a Biopsy?

What Is a Biopsy? Everything You Need to Know →

Types of Biopsy Compared

Which Biopsy Will You Have? Techniques Compared →

Preparing for a Biopsy

What to Expect on the Day of Your Biopsy →

Recovery and Aftercare

After a Biopsy: Recovery, Aftercare and Warning Signs →

Biopsy by Body Part

Biopsy by Body Part: What to Expect at Each Site →

Understanding Your Report

How to Read a Biopsy Report: Terms Explained →

IHC and Molecular Markers

IHC and Molecular Markers on a Biopsy: What They Mean →

Grading and Scoring Systems

Cytology & Prostate Scoring Systems Explained →

How Accurate Is a Biopsy?

How Accurate Is a Biopsy? Errors and Second Opinions →

If Your Result Is Benign

Your Biopsy Is Benign: What It Means and What Comes Next →

Call now Book free consultation